[Skip to Content]
[Skip to Content Landing]
December 13, 1965

Group A β-Hemolytic Streptococcal Pharyngitis—Results of Treatment With Lincomycin

Author Affiliations

From the Fort Morgan Medical Group, Fort Morgan, Colo.

JAMA. 1965;194(11):1189-1192. doi:10.1001/jama.1965.03090240023005

A controlled study was done to determine the effectiveness of lincomycin in treating pharyngitis due to group A β-hemolytic streptococcus. Included in the study were 870 patients with either a positive culture or a clinical disease serious enough to warrant treatment with antibiotics. They were allocated alternately to a lincomycin-treated group (429 patients) or to a penicillin-treated control group (441 patients). Initial cultures were positive for group A β-hemolytic streptococci in 140 of the lincomycin group and 125 of the penicillin group. Followup cultures on these patients were negative in 131 (93%) of those treated with lincomycin and 111 (89%) of those treated with penicillin. The lincomycin was as effective as penicillin, acceptable in all dosage forms, and had a low incidence of side effects.